Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2023


	September 30,		December 31,
	2023		2022
Accrued interest on preferred members’ interests	$	188,085	$	188,085
Accrued compensation		46,799		159,704
Accrued professional fees		16,650		11,600
Accrued clinical research costs		9,000		78,349
Accrued director fees		15,500		31,000
Other miscellaneous accrued expenses		5,741		1,360
	$	281,775	$	470,098